SCHEMBL4729614

SCHEMBL4729614

COc1cc(N)c2nc(C34CC5CC(CC(C5)C3)C4)ccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
ALDH1A1 P00352 5/20 0.36
LMNA P02545 4/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
NR1I2 O75469 1/20 0.35
PGR P06401 1/20 0.35
RARA P10276 1/20 0.35
HSPD1 P10809 1/20 0.35
RARB P10826 1/20 0.35
RARG P13631 1/20 0.35
GOT1 P17174 1/20 0.35
GLRA1 P23415 1/20 0.35
BLM P54132 1/20 0.35
HSPE1 P61604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4728485 0.79 LMNA (0.40) IDO1TDO2ALDH1A1LMNASMN1; SMN2
SCHEMBL4729616 0.75 CYP2D6 (0.35) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL441572 0.70 NFKBIA (0.52) ALDH1A1LMNASMN1; SMN2KDM4EMEN1
SCHEMBL12120522 0.69 NCF1 (0.45) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL11690033 0.69 MEN1 (0.44) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL11640397 0.68 ALDH1A1 (0.44) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL4729566 0.67 NFKBIA (0.41) ALDH1A1LMNASMN1; SMN2KDM4EMEN1
SCHEMBL11545623 0.67 NCF1 (0.39) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL11542086 0.66 KDM4E (0.44) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL11544082 0.66 NCF1 (0.38) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008021210-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS COMBINATORX, INCORPORATED (US) 2008-02-21 WO disclosed
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders CHDI, INCORPORATED 2008-02-21 US disclosed
US-6979740-B2 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) 2005-12-27 US disclosed
EP-1606263-A1 RING-SUBSTITUTED 8-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIAL AGENTS Council of Scientific and Industrial Research (IN) 2005-12-21 EP disclosed
WO-2004085402-A1 RING-SUBSTITUTED 8-AMINOQUNOLINE DERIVATES AS ANTIMALARIAL AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2004-10-07 WO disclosed
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents QDPR, SLC11A2, CYP2C8 IDO1 636/4885TDO2 3041/4885ALDH1A1 673/4885
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders HTT, SNCA, NLN IDO1 3809/4885TDO2 4183/4885ALDH1A1 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.